BlueChip Wealth Advisors LLC Sells 346 Shares of Johnson & Johnson (NYSE:JNJ)

BlueChip Wealth Advisors LLC lessened its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 12.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,458 shares of the company’s stock after selling 346 shares during the period. BlueChip Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $355,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. IFS Advisors LLC lifted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after purchasing an additional 100 shares in the last quarter. WealthTrak Capital Management LLC bought a new stake in Johnson & Johnson in the 4th quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. acquired a new position in Johnson & Johnson during the 4th quarter worth approximately $29,000. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. The trade was a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of the stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Up 0.3 %

Johnson & Johnson stock opened at $163.63 on Friday. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The stock has a market cap of $394.32 billion, a P/E ratio of 24.61, a P/E/G ratio of 2.56 and a beta of 0.47. The company’s 50-day moving average price is $158.68 and its two-hundred day moving average price is $156.21. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The business had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same period last year, the firm posted $2.29 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. As a group, analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.03%. The ex-dividend date of this dividend was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of several recent research reports. Raymond James reduced their target price on shares of Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, February 19th. Leerink Partners lowered their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Wells Fargo & Company reduced their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating for the company in a research report on Thursday, January 23rd. Finally, Morgan Stanley lowered their price target on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $171.33.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.